Inhibrx Announces Participation in Upcoming Scientific Conferences

Inhibrx Biosciences, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company, has announced its participation in several upcoming scientific conferences where it will present new data on its therapeutic candidates focusing on novel biologic treatments. The company is scheduled to speak at three key events, showcasing its work on the tetravalent Death Receptor 5 (DR5) agonist, ozekibart (INBRX-109).

The first presentation will occur at the 21st Annual Industry/Academia Precision Oncology & Radmed Symposium in La Jolla, California, on November 5, 2025. Inhibrx executives, Dr. Josep Garcia and Dr. Katelyn Willis, will present clinical data concerning DR5 agonist applications in treating chondrosarcoma, colorectal cancer, and Ewing sarcoma, highlighting their promising findings and therapeutic strategies.

Following this, Inhibrx will present at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting from November 12-15, 2025, in Boca Raton, Florida. Here, Dr. Robin L. Jones will discuss the results of the randomized, registrational Phase 2 ChonDRAgon study focused on the efficacy of ozekibart in conventional chondrosarcoma.

Finally, the company will present a poster at the Society for NeuroOncology (SNO) 2025 Annual Meeting in Honolulu, Hawaii, from November 19-23, 2025. This presentation will detail the anti-tumor activity of ozekibart in glioblastoma (GBM) models, both as a standalone treatment and in combination with temozolomide.

All presentations will be accessible through a dedicated link on Inhibrx's investor relations website, allowing interested parties to follow their advancements in biopharmaceutical research. With a focus on developing innovative treatments, Inhibrx aims to address complex disease biology through its proprietary protein engineering platforms.

Inhibrx Biosciences, Inc. (Nasdaq: INBX) has recently announced its participation in several key scientific conferences, which could present a critical opportunity for investors to evaluate the company's strategic positioning and market potential. The presentations, particularly those focused on their Tetravalent Death Receptor 5 (DR5) agonist, ozekibart, will showcase data that could significantly impact investor sentiment and the stock's performance.

The participation in the 21st Annual Industry/Academia Precision Oncology & Radmed Symposium and subsequent conferences, including the CTOS 2025 Annual Meeting and Society for NeuroOncology (SNO) 2025 Annual Meeting, highlights Inhibrx's commitment to transparency and collaboration within the scientific community. Presentations on clinical data related to chondrosarcoma, colorectal cancer, and glioblastoma multiforme (GBM) underscore the therapeutic advancements the company is making in its clinical pipeline. As these conferences often serve as a platform for validating research claims, positive reception to their findings could catalyze upward movement in stock price.

However, potential investors should also weigh the inherent risks of investing in clinical-stage biopharmaceutical companies. The success of ozekibart and other candidates hinges on ongoing clinical trial results, which are fraught with uncertainty. Market reactions can be volatile, particularly surrounding data releases and conference presentations.

Given the upcoming presentations, it may be prudent for investors to monitor stock performance closely, especially for signs of increased trading volume or price appreciation in the lead-up to these events. Long-term prospects could remain robust if clinical data aligns with current market expectations. Diversifying exposure while keeping abreast of biopharmaceutical developments may mitigate risks while capitalizing on potential upside from Inhibrx's innovative pipeline. Make informed decisions based on both market movements and clinical data releases.